Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/22089374/ below:

Projected life expectancy of people with HIV according to timing of diagnosis

Affiliations

• ¹ HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, University College London, UK. f.nakagawa@ucl.ac.uk

• PMID: 22089374
• DOI: 10.1097/QAD.0b013e32834dcec9

Item in Clipboard

Fumiyo Nakagawa et al. AIDS. 2012.

• ¹ HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, University College London, UK. f.nakagawa@ucl.ac.uk

• PMID: 22089374
• DOI: 10.1097/QAD.0b013e32834dcec9

Item in Clipboard

Background and objectives: Effective antiretroviral therapy (ART) has contributed greatly toward survival for people with HIV, yet many remain undiagnosed until very late. Our aims were to estimate the life expectancy of an HIV-infected MSM living in a developed country with extensive access to ART and healthcare, and to assess the effect of late diagnosis on life expectancy.

Methods: A stochastic computer simulation model of HIV infection and the effect of ART was used to estimate life expectancy and determine the distribution of potential lifetime outcomes of an MSM, aged 30 years, who becomes HIV positive in 2010. The effect of altering the diagnosis rate was investigated.

Results: Assuming a high rate of HIV diagnosis (median CD4 cell count at diagnosis, 432 cells/μl), projected median age at death (life expectancy) was 75.0 years. This implies 7.0 years of life were lost on average due to HIV. Cumulative risks of death by 5 and 10 years after infection were 2.3 and 5.2%, respectively. The 95% uncertainty bound for life expectancy was (68.0,77.3) years. When a low diagnosis rate was assumed (diagnosis only when symptomatic, median CD4 cell count 140 cells/μl), life expectancy was 71.5 years, implying an average 10.5 years of life lost due to HIV.

Conclusion: If low rates of virologic failure observed in treated patients continue, predicted life expectancy is relatively high in people with HIV who can access a wide range of antiretrovirals. The greatest risk of excess mortality is due to delays in HIV diagnosis.

PubMed Disclaimer

• Life expectancy among HIV-positive patients in Rwanda: a retrospective observational cohort study.

  Nsanzimana S, Remera E, Kanters S, Chan K, Forrest JI, Ford N, Condo J, Binagwaho A, Mills EJ. Nsanzimana S, et al. Lancet Glob Health. 2015 Mar;3(3):e169-77. doi: 10.1016/S2214-109X(14)70364-X. Lancet Glob Health. 2015. PMID: 25701995

• Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada.

  Patterson S, Cescon A, Samji H, Chan K, Zhang W, Raboud J, Burchell AN, Cooper C, Klein MB, Rourke SB, Loutfy MR, Machouf N, Montaner JS, Tsoukas C, Hogg RS; CANOC collaboration. Patterson S, et al. BMC Infect Dis. 2015 Jul 17;15:274. doi: 10.1186/s12879-015-0969-x. BMC Infect Dis. 2015. PMID: 26183704 Free PMC article.

• Cost-Effectiveness Analysis of Early vs Late Diagnosis of HIV-Infected Patients in South Carolina.

  Rampaul M, Edun B, Gaskin M, Albrecht H, Weissman S. Rampaul M, et al. South Med J. 2018 Jun;111(6):355-358. doi: 10.14423/SMJ.0000000000000819. South Med J. 2018. PMID: 29863227

• The lifetime cost of current human immunodeficiency virus care in the United States.

  Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Weinstein MC, Seage GR 3rd, Moore RD, Freedberg KA. Schackman BR, et al. Med Care. 2006 Nov;44(11):990-7. doi: 10.1097/01.mlr.0000228021.89490.2a. Med Care. 2006. PMID: 17063130 Review.

• Processes and outcomes of developing a continuity of care document for use as a personal health record by people living with HIV/AIDS in New York City.

  Gordon P, Camhi E, Hesse R, Odlum M, Schnall R, Rodriguez M, Valdez E, Bakken S. Gordon P, et al. Int J Med Inform. 2012 Oct;81(10):e63-73. doi: 10.1016/j.ijmedinf.2012.06.004. Epub 2012 Jul 26. Int J Med Inform. 2012. PMID: 22841825 Free PMC article.

• Evaluation of rapid antiretroviral initiation strategy in a cohort of newly diagnosed people living with HIV in Panama, 2018-2019.

  Alvis-Estrada JP, Azmitia-Rugg A, Sobalvarro-Stolz X, Romo-Dueñas D, Díaz F, Martínez A, Morales RE, Chang LR, Vega N, Araúz AB, Ávila-Montes G. Alvis-Estrada JP, et al. AIDS Care. 2024 Nov;36(11):1588-1595. doi: 10.1080/09540121.2024.2373397. Epub 2024 Jul 11. AIDS Care. 2024. PMID: 38991109 Free PMC article.

• Smoking: A Major Roadblock in the Fight Against AIDS.

  Siddiqi K, Mdege N. Siddiqi K, et al. Nicotine Tob Res. 2016 Dec;18(12):2175-2176. doi: 10.1093/ntr/ntw130. Epub 2016 May 4. Nicotine Tob Res. 2016. PMID: 27146640 Free PMC article. No abstract available.

• Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study).

  Sullivan AK, Raben D, Reekie J, Rayment M, Mocroft A, Esser S, Leon A, Begovac J, Brinkman K, Zangerle R, Grzeszczuk A, Vassilenko A, Hadziosmanovic V, Krasnov M, Sönnerborg A, Clumeck N, Gatell J, Gazzard B, Monforte Ad, Rockstroh J, Lundgren JD. Sullivan AK, et al. PLoS One. 2013;8(1):e52845. doi: 10.1371/journal.pone.0052845. Epub 2013 Jan 15. PLoS One. 2013. PMID: 23341910 Free PMC article.

• Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV.

  Merlini E, Cozzi-Lepri A, Castagna A, Costantini A, Caputo SL, Carrara S, Quiros-Roldan E, Ursitti MA, Antinori A, D'Arminio Monforte A, Marchetti G. Merlini E, et al. BMC Infect Dis. 2021 Jun 12;21(1):557. doi: 10.1186/s12879-021-06260-y. BMC Infect Dis. 2021. PMID: 34116650 Free PMC article.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3